Go Pro
NASDAQ:BEAT

HeartBeam (BEAT) Stock Price, News & Analysis

HeartBeam logo
$0.50 +0.00 (+0.98%)
Closing price 08/4/2026 04:00 PM Eastern
Extended Trading
$0.50 +0.01 (+1.09%)
As of 08:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About HeartBeam Stock (NASDAQ:BEAT)

Advanced

Key Stats

Today's Range
$0.49
$0.51
50-Day Range
$0.49
$0.91
52-Week Range
$0.48
$4.00
Volume
487,757 shs
Average Volume
1.07 million shs
Market Capitalization
$27.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Moderate Buy

Company Overview

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.

HeartBeam Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

BEAT MarketRank™: 

HeartBeam scored higher than 49% of companies evaluated by MarketBeat, and ranked 529th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    HeartBeam has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 5 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    HeartBeam has a consensus price target of $4.00, representing about 705.5% upside from its current price of $0.50.

  • Amount of Analyst Coverage

    HeartBeam has only been the subject of 4 research reports in the past 90 days.

  • Read more about HeartBeam's stock forecast and price target.
  • Earnings Growth

    Earnings for HeartBeam are expected to grow in the coming year, from ($0.38) to ($0.30) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of HeartBeam is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of HeartBeam is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    HeartBeam has a P/B Ratio of 8.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about HeartBeam's valuation and earnings.
  • Percentage of Shares Shorted

    5.58% of the float of HeartBeam has been sold short.
  • Short Interest Ratio / Days to Cover

    HeartBeam has a short interest ratio ("days to cover") of 1.51, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in HeartBeam has recently increased by 42.02%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    HeartBeam does not currently pay a dividend.

  • Dividend Growth

    HeartBeam does not have a long track record of dividend growth.

  • News Sentiment

    HeartBeam has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for HeartBeam this week, compared to 4 articles on an average week.
  • Search Interest

    Only 2 people have searched for BEAT on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added HeartBeam to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, HeartBeam insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    17.95% of the stock of HeartBeam is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    7.77% of the stock of HeartBeam is held by institutions.

  • Read more about HeartBeam's insider trading history.
Receive BEAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HeartBeam and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BEAT Stock News Headlines

Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Contrasting HeartBeam (NASDAQ:BEAT) and Phreesia (NYSE:PHR)
See More Headlines

BEAT Stock Analysis - Frequently Asked Questions

HeartBeam's stock was trading at $2.3950 on January 1st, 2026. Since then, BEAT stock has decreased by 79.3% and is now trading at $0.4966.

HeartBeam, Inc. (NASDAQ:BEAT) released its quarterly earnings results on Wednesday, May, 13th. The medical research company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02.
Read the conference call transcript
.

HeartBeam (BEAT) raised $16 million in an initial public offering on Thursday, November 11th 2021. The company issued 2,750,000 shares at a price of $5.50-$6.50 per share.

Shares of BEAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that HeartBeam investors own include NVIDIA (NVDA), Meta Platforms (META), Bristol Myers Squibb (BMY), Intel (INTC), Micron Technology (MU), PayPal (PYPL) and AbbVie (ABBV).

Company Calendar

Last Earnings
5/13/2026
Today
8/05/2026
Next Earnings (Estimated)
8/13/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:BEAT
CIK
1574774
Fax
N/A
Employees
1,700
Year Founded
N/A

Price Target and Rating

High Price Target
$5.50
Low Price Target
$2.00
Potential Upside/Downside
+705.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.56)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$21.01 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-1,034.04%
Return on Assets
-434.40%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.74
Quick Ratio
0.70

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.06 per share
Price / Book
8.28

Miscellaneous

Outstanding Shares
55,510,000
Free Float
45,543,000
Market Cap
$27.57 million
Optionable
Not Optionable
Beta
-0.78
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:BEAT) was last updated on 8/5/2026 by MarketBeat.com Staff.
From Our Partners